1-20 of 7933
Sort by
Journal Article
ACCEPTED MANUSCRIPT
Merve Direktor and others
International Journal of Neuropsychopharmacology, pyae018, https://doi.org/10.1093/ijnp/pyae018
Published: 17 April 2024
Journal Article
ACCEPTED MANUSCRIPT
Samuel Pintos-Rodríguez and others
International Journal of Neuropsychopharmacology, pyae020, https://doi.org/10.1093/ijnp/pyae020
Published: 11 April 2024
Journal Article
ACCEPTED MANUSCRIPT
Nathan T M Huneke and others
International Journal of Neuropsychopharmacology, pyae019, https://doi.org/10.1093/ijnp/pyae019
Published: 05 April 2024
Journal Article
ACCEPTED MANUSCRIPT
Sumra Sajid and others
International Journal of Neuropsychopharmacology, pyae017, https://doi.org/10.1093/ijnp/pyae017
Published: 04 April 2024
Journal Article
ACCEPTED MANUSCRIPT
Gessica Piras and others
International Journal of Neuropsychopharmacology, pyae016, https://doi.org/10.1093/ijnp/pyae016
Published: 28 March 2024
Image
Published: 28 March 2024
Graphical Abstract Graphical abstract
Journal Article
International Journal of Neuropsychopharmacology, Volume 27, Issue 3, March 2024, pyae004, https://doi.org/10.1093/ijnp/pyae004
Published: 26 March 2024
Journal Article
Pascal Ibrahim and others
International Journal of Neuropsychopharmacology, Volume 27, Issue 3, March 2024, pyae013, https://doi.org/10.1093/ijnp/pyae013
Published: 08 March 2024
Image
Published: 08 March 2024
Figure 1. Schematic diagram representing study workflow. CTRL, control; F1, fraction 1; F2, fraction 2; MDD, major depressive disorder. Figure was created using BioRender.
Image
Published: 08 March 2024
Figure 2. Quality assessment of EV isolation. (A) Left: Representative stain-free image showing total protein loading for western blot. Right: Representative western blot for Calnexin, BiP, VDAC, CD9, and TSG101 in F1, F2, WB, and PC. (B) Average distribution of particle size from 20 subjects (5 M-CTRL, 5 M-M
Image
Published: 08 March 2024
Figure 3. Comparative analysis of EV miRNAs in males and females. (A) Volcano plots showing altered miRNA expression for males (blue) and females (orange) at a cut-off of P value ≤ .05. (B) Correlation plots between normalized sequencing counts and qPCR expression of the 3 top miRNAs for males (blue) and fe
Journal Article
Ajna Hamidovic and others
International Journal of Neuropsychopharmacology, Volume 27, Issue 3, March 2024, pyae015, https://doi.org/10.1093/ijnp/pyae015
Published: 07 March 2024
Image
Published: 07 March 2024
Figure 1. The effect of time and diagnosis on serum cortisol. Considering the baseline, PMDD participants had lower cortisol levels at +40 ( P  ≤ .01), +50 ( P  ≤ .01), +65 ( P  ≤ .01), and +90 ( P  ≤ .01) minutes from the start of TSST relative to the healthy controls. The intervals represent confidence inte
Image
Published: 05 March 2024
Figure 2. Change over time in Oxford Depression Questionnaire (ODQ) score and subscales over time by treatment group. Plots of the mean of vortioxetine + placebo and vortioxetine + celecoxib scores at baseline, week 8, 3-month follow-up, and 6-month follow-up time points for a ODQ total score, b ODQ gener
Image
Published: 05 March 2024
Figure 3. Change over time in Oxford Depression Questionnaire (ODQ) score and subscales over time by treatment group and high sensitivity C-reactive protein (hsCRP) strata. Plots of the mean respective scores at baseline, week 8, 3-month follow-up, and 6-month follow-up time points of participants treated wit
Journal Article
Emma Sampson and others
International Journal of Neuropsychopharmacology, Volume 27, Issue 3, March 2024, pyad066, https://doi.org/10.1093/ijnp/pyad066
Published: 05 March 2024
Image
Published: 05 March 2024
Figure 1. PREDDICT RCT schedule of treatments and assessments a . a Adapted from Kavakbasi et al. , 2023 . A, administration of the Oxford Depression Questionnaire (ODQ) assessment; B, collection of peripheral venous blood; R, randomization. Participation in the trial and continued treatment with vo
Image
Published: 26 February 2024
Figure 3. Forest plot of comparison in the risk ratio of conversion to psychosis in the network meta-analysis for transition outcome at 6, 12, and ≥24 months in 2 levels: pharmacological/nutritional interventions group (on the left) and pharmacological/nutritional interventions plus psychotherapy group (on th
Image
Published: 26 February 2024
Figure 2. Network plots of direct comparisons in the network meta-analysis for transition outcome at 6, 12, and ≥24 months in 2 levels: pharmacological/nutritional interventions group (on the left) and pharmacological/nutritional interventions plus psychotherapy group (on the right). The width of the lines is
Journal Article
Chengfeng Chen and others
International Journal of Neuropsychopharmacology, Volume 27, Issue 3, March 2024, pyae014, https://doi.org/10.1093/ijnp/pyae014
Published: 26 February 2024